UNSPSC 51434948: Hydrochlorothiazide/reserpine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.

UNSPSC 51434948 Hydrochlorothiazide/reserpine is a Commodity code under which state and local governments procure emergency and critical-care medications for fire rescue departments, health agencies, and cooperative purchasing consortiums. The code reflects demand for specific pharmaceutical line items—individual drug products with defined strengths, dosages, and vial or injection formats—supplied in quantities ranging from hundreds to thousands of units per contract. Issuing bodies include city purchasing departments acting on behalf of fire and rescue services, state health and human services commissions, and multistate cooperative purchasing alliances. The work involves pharmaceutical sourcing, supply-chain coordination through authorized wholesalers, compliance with FDA and cGMP standards, hazardous-materials documentation, and expiration-date management.

Recent activity centers in Florida and Minnesota, with early exploratory procurement in Texas. The City of Tampa's Purchasing Department issued IFB 26P00188 in April 2026 seeking Advanced Life Support Medications—including Labetalol, Epinephrine, Adenosine, and Diltiazem—for Tampa Fire Rescue, with a response deadline of April 8, 2026 and an estimated contract value of $40,000, incorporating a 5 percent SLBE bid discount. The Minnesota Department of Administration's Office of State Procurement, on behalf of MMCAP, released RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products across state and local government facilities in Minnesota and Oregon, with responses due March 26, 2026 and contract effectiveness targeted for July 1, 2026. The Texas Health and Human Services Commission posted RFI HHS0017013 in late March 2026 to gather vendor capabilities on direct-to-manufacturer prescription programs, signaling exploratory procurement intent but no formal competitive solicitation to date.